PropertyValue
?:abstract
  • The 2019 coronavirus disease (COVID-19) pandemic is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Clinical outcomes, including mortality, are worse in males, older individuals and patients with comorbidities. COPD patients are included in shielding strategies due to their susceptibility to virus-induced exacerbations, compromised pulmonary function and high prevalence of associated comorbidities. Using evidence from basic science and cohort studies, this review addresses key questions concerning COVID-19 and COPD. First, are there mechanisms by which COPD patients are more susceptible to SARS-CoV-2 infection? Secondly, do inhaled corticosteroids offer protection against COVID-19? And, thirdly, what is the evidence regarding clinical outcomes from COVID-19 in COPD patients? This up-to-date review tackles some of the key issues which have significant impact on the long-term outlook for COPD patients in the context of COVID-19.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1183/16000617.0199-2020
?:journal
  • Eur_Respir_Rev
?:license
  • cc-by-nc
?:pdf_json_files
  • document_parses/pdf_json/9e6ceb50f8b1997996bacd44c2da290c675a800c.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7651840.xml.json
?:pmcid
?:pmid
?:pmid
  • 33153991.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • COVID-19 and COPD: a narrative review of the basic science and clinical outcomes
?:type
?:year
  • 2020-11-04

Metadata

Anon_0  
expand all